Recently, the Vaccine International Cooperation Promotion Branch of the China Vaccine Industry Association (hereinafter referred to as the "National Promotion Branch") held the "Vaccine International Cooperation Ecological Seminar Forum" during the 22nd China Biological Products Annual Conference, and released and interpreted the "China Vaccine Industry International Cooperation Development Report 2023" (hereinafter referred to as the "Report") at the forum. According to the introduction, the report analyzed and scanned the global vaccine industry and market opportunities, sorted out the paths and pain points of enterprises going overseas, and provided systematic suggestions to address these challenges. The report believes that under the influence of internal and external factors, internationalization will become a "compulsory course" for Chinese vaccine companies. It is expected that in the future, more Chinese vaccine companies will go abroad and enter the world, "said Ma Haihong, Deputy Secretary General of the China National Association for the Promotion of Vaccines and Senior Strategic Officer of the Zhongyi Beijing Health Research Institute. With the support of the China Vaccine Industry Association, the China National Association for the Promotion of Vaccines will build an international comprehensive service platform for academic exchange and industrial cooperation in the vaccine industry, promoting mutual exchange and learning from each other to help Chinese vaccine companies go overseas, Contribute Chinese wisdom to the cause of global health. The report outlines the "seven major paths" for Chinese vaccine companies to go overseas, divided into three levels based on maturity: high, medium, and low. Among them, entering international procurement through pre certification by the World Health Organization is one of the high maturity paths. Since the first domestically produced vaccine passed WHO pre certification in 2013, 10 Chinese vaccines have passed pre certification. In continuous exploration, vaccine companies have gradually realized that pre certification is a stepping stone to enter the low and middle-income market and a touchstone for their ability to go global; At the same time, pre certification also allows enterprises to receive rewards in terms of commercial value. The report also summarizes the "five pain points" of Chinese vaccine companies going overseas, divided into two levels: internal and external. At the internal level, the lack of high-level awareness and internationalization strategies, the need to improve internationalization and core business capabilities, and the need to coordinate regulatory policies with industry internationalization are common challenges faced by Chinese vaccine companies. At the external level, the construction of local partner networks is still in its early stages, and the lack of local resources and talent often hinders the implementation of internationalization strategies. In response to these common challenges, the report provides three suggestions for Chinese vaccine companies. One is to change the concept of going to sea and tailor strategies accordingly. Company decision-makers should continuously broaden their international perspective and establish a triple internationalization concept of "value oriented", "systematic", and "long-term". The second is to strengthen communication with regulatory authorities and jointly seek solutions to problems. Leading enterprises can strengthen communication to reach industry consensus, discuss the most urgent issues, and strive for communication and discussion with regulatory agencies. Empathize with the uniqueness and niche of vaccine products, understand the bottom line of regulatory risk control, and strive for appropriate innovation and pilot space. Thirdly, enterprises need to enhance their core capabilities and participate in international communities. Vaccine companies that aspire to go global should start from today by combining internal capabilities and overseas markets to achieve both internal and external development. Actively participating in international activities and community building will be beneficial for the long-term development of the company. (New News Agency)